Skip to main content

In-111 Zevalin Side Effects

Generic name: ibritumomab

Medically reviewed by Drugs.com. Last updated on Mar 30, 2024.

Note: This document contains side effect information about ibritumomab. Some dosage forms listed on this page may not apply to the brand name In-111 Zevalin.

Applies to ibritumomab: intravenous solution.

Warning

Intravenous route (Solution)

Serious infusion reactions, including fatalities, have occurred within 24 hours of rituximab infusion, an essential component of the ibritumomab tiuxetan therapeutic regimen. Most fatal infusion reactions (80%) occurred with the first rituximab infusion. Administration also results in severe and prolonged cytopenias in most patients. The ibritumomab tiuxetan therapeutic regimen should not be administered to patients with 25% or greater lymphoma marrow involvement and/or impaired bone marrow reserve. Severe cutaneous and mucocutaneous reactions, some with fatal outcome, can occur with therapy. The dose of Y-90 ibritumomab tiuxetan should not exceed the absolute maximum allowable dose of 32 millicurie (1184 megabecquerels).

Serious side effects of In-111 Zevalin

Along with its needed effects, ibritumomab (the active ingredient contained in In-111 Zevalin) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ibritumomab:

More common

Less common

Rare

Incidence not known

Other side effects of In-111 Zevalin

Some side effects of ibritumomab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For several months after receiving this therapy, it may still produce some side effects that need attention. During this period of time check with your doctor immediately if you notice any of the following:

For Healthcare Professionals

Applies to ibritumomab: intravenous kit.

Cardiovascular

Common (1% to 10%): Hypertension[Ref]

Dermatologic

Common (1% to 10%): Night sweats, petechiae, pruritus, rash

Postmarketing reports: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis[Ref]

Gastrointestinal

Very common (10% or more): Nausea, abdominal pain, diarrhea[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Hematologic

Very common (10% or more): Thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia

Common (1% to 10%): Ecchymosis

Frequency not reported: Cytopenias[Ref]

Local

Postmarketing reports: Infusion site erythema, ulceration following extravasation[Ref]

Metabolic

Common (1% to 10%): Anorexia[Ref]

Musculoskeletal

Common (1% to 10%): Myalgia[Ref]

Nervous system

Common (1% to 10%): Dizziness[Ref]

Oncologic

Frequency not reported: Secondary malignancy[Ref]

Other

Very common (10% or more): Fatigue, asthenia, pyrexia, serious and life threatening infections

Common (1% to 10%): Influenza-like illness

Uncommon (0.1% to 1%): Antibody formation

Postmarketing reports: Radiation injury[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (19%), cough (11%)

Common (1% to 10%): Pharyngolaryngeal pain, epistaxis, bronchitis, rhinitis, sinusitis[Ref]

More about In-111 Zevalin (ibritumomab)

Patient resources

Professional resources

Other formulations

Related treatment guides

References

1. "Product Information. In-111 Zevalin (ibritumomab tiuxetan)." IDEC Pharmaceuticals Corporation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.